Executive Vice President, Chief Medical Officer · BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Ibrahim Dagher

FY2024 is the first fiscal year CompBrief holds for Ibrahim Dagher as a named executive officer of BRAINSTORM CELL THERAPEUTICS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$498,578

Salary $294,000Stock awards $71,855Bonus $103,750

2nd of 4 named executive officers at Brainstorm Cell Therapeutics by FY2024 total.

4 named officers on file for BRAINSTORM CELL THERAPEUTICS, FY2024

Ibrahim Dagher’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how BRAINSTORM CELL THERAPEUTICS’s whole pay program stands against its peers

  • BRAINSTORM CELL THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on BCLI→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 31, 2026 (10-K). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Ibrahim Dagher’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Ibrahim Dagher compensation by year

BRAINSTORM CELL THERAPEUTICS Summary Compensation Table · the one fiscal year held
In US dollars, as BRAINSTORM CELL THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$294,000
Bonus$103,750
Stock awards$71,855
Option awards$0
Non-equity incentive$0
Pension and deferred compensation$0
All other$28,973
Total$498,578

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BRAINSTORM CELL THERAPEUTICS INC. 10-K filed March 31, 2026, accession 0001104659-26-037927, and prior-year filings.

How this page was built: the BRAINSTORM CELL THERAPEUTICS INC. filed document, accession 0001104659-26-037927. Every figure is read from that document and cited to the page and table it appears in. Filed March 31, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU25,000$13,750—
RSU7,258$3,992—
Option2,333—$25.95

Per the Outstanding Equity Awards at Fiscal Year-End table in BRAINSTORM CELL THERAPEUTICS INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

1 Form 4 line since the FY2024 proxy (filed March 31, 2026)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-02-26Grant or award derivative—225,000$0.70225,000

The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

BRAINSTORM CELL THERAPEUTICS’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Chaim LebovitsChief Executive Officer & President$750,303
Ibrahim Dagher · this pageExecutive Vice President, Chief Medical Officer$498,578
Stacy LindborgFormer Co-Chief Executive Officer$346,375
Uri YablonkaExecutive Vice President, Chief Business Officer, Secretary and Director$266,138

The full BRAINSTORM CELL THERAPEUTICS compensation record

free company brief

This page is one person within BRAINSTORM CELL THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BRAINSTORM CELL THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Ibrahim Dagher's compensation dossier · One-time report. No refunds.